炎症性肠病
医学
免疫系统
机制(生物学)
疾病
干预(咨询)
溃疡性结肠炎
桥接(联网)
生物信息学
临床实习
炎症
药品
炎症性肠病
免疫学
克罗恩病
重症监护医学
肠道菌群
细胞外
转化研究
药物输送
药物发现
药物开发
细胞外小泡
临床试验
靶向给药
肠易激综合征
药理学
计算生物学
人体研究
促炎细胞因子
炎症反应
临床疗效
失调
作者
Yimeng Wang,Yuning Zhang,Sijia Song,Juan Chen,Huiyuan Guo,Yingying Lin
标识
DOI:10.1080/10408398.2025.2603666
摘要
BACKGROUND: Food-derived extracellular vesicles (FEVs) from plants, milk and probiotics are emerging as bioactive nanocarriers linking nutrition and metabolism. Their natural stability provides unique advantages for gastrointestinal therapeutics. Inflammatory bowel disease (IBD) is a refractory intestinal disease, and the current research shows that FEVs have potential application value in improving IBD. Scope and Approach: This review systematically summarizes the current understanding of FEVs from three major sources-plant-derived, milk-derived, and bacteria-derived EVs, encompassing their biogenesis, structural characteristics, application characteristics and mechanism of action, with emphasis on their role in IBD intervention. And put forward new strategies and prospects for FEVs' intervention and application in IBD, providing a comprehensive perspective for their role in nutrition intervention. KEY FINDINGS AND CONCLUSIONS: FEVs from distinct sources exhibit characteristic structural and functional profiles that enable source-specific intervention strategies for IBD. These natural nanovesicles demonstrate multi-modal therapeutic effects by modulating gut microbiota composition, enhancing intestinal barrier integrity, and fine-tuning immune responses. Their role as nutritional modulators and drug delivery vehicles holds significant clinical promise for IBD management. However, translational challenges persist, including mechanism uncertainties, suboptimal targeting efficiency, unverified long-term safety, and limited production yields. Future studies should prioritize bridging these knowledge gaps to facilitate FEV-based clinical translation.
科研通智能强力驱动
Strongly Powered by AbleSci AI